Loading
A phase 2 trial of Durvalumab, Oleclumab, Monalizumab in non-small-cell lung cancer and small-cell lung cancer, run by AstraZeneca, now recruiting.
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer is a phase 2 interventional study registered as NCT05061550 by AstraZeneca, with 630 participants planned, started 2022-04-14 and due to reach its primary completion in 2030-05-28. Interventions recorded: Durvalumab, Oleclumab, Monalizumab, Dato-DXd, AZD0171. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Monalizumab, Oleclumab, AstraZeneca, Non-small-cell lung cancer.
Shares Oleclumab, Durvalumab, AstraZeneca, Small-cell lung cancer.
Shares Monalizumab, Oleclumab, Durvalumab, AstraZeneca.
Shares Datopotamab deruxtecan, Resectable stage I to III non-small-cell lung cancer, AstraZeneca, Cisplatin.
Shares Resectable stage I to III non-small-cell lung cancer, AstraZeneca, Cisplatin, Carboplatin.
Shares Resectable stage I to III non-small-cell lung cancer, Durvalumab, AstraZeneca, Small-cell lung cancer.
Shares Datopotamab deruxtecan, Durvalumab, AstraZeneca, Cisplatin.
Shares Durvalumab, AstraZeneca, Cisplatin, Carboplatin.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/